EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis

Nikolaos Dimisianos iD, Maria Rodi, Dimitra Kalavrizioti iD, Vasileios Georgiou, Panagiotis Papathanasopoulos, Athanasia Mouzaki

Multiple Sclerosis International · 2014 · 2014 · 1-8

DOI: 10.1155/2014/436764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis International, 2014. Verfasst von Nikolaos Dimisianos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Patras University Hospital, 26500 Patras, Greece. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Greek General Secretariat of Research and Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable.

Objective

To find a biomarker for treatment response to IFN β among pro- and anti-inflammatory cytokines. Materials and Methods . IFN- γ , TNF- α , IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF- β 1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFN β treatment and were divided into good responders (GR, n = 19) and poor responders (PR, n = 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx).

Results

GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN- γ , TNF- α , and IL-2 than noRx. PR had significantly higher IFN- γ serum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF- β 1 or the levels of all cytokines measured in CSF between the 3 groups of patients.

Conclusions

Baseline serum levels of IL-17A can be used as a biomarker of IFN β treatment response.

Autor:innen und Institutionen

  • Department of Neurology, Patras University Hospital, 26500 Patras, Greece.
  • Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26500 Patras, Greece.
  • Hellenic Open University, Parodos Aristotelous 18, 26335 Patras, Greece.

ORCID-Profile: Nikolaos Dimisianos, Dimitra Kalavrizioti

Förderung

  • Greek General Secretariat of Research and Technology

Zitieren

APA

Dimisianos, N., Rodi, M., Kalavrizioti, D., Georgiou, V., Papathanasopoulos, P., & Mouzaki, A. (2014). Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis International, 2014, 1-8. https://doi.org/10.1155/2014/436764

Vancouver

Dimisianos N, Rodi M, Kalavrizioti D, Georgiou V, Papathanasopoulos P, Mouzaki A. Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis International. 2014;2014:1-8. doi:10.1155/2014/436764

BibTeX
@article{Dimisianos2014,
  author = {Dimisianos, Nikolaos and Rodi, Maria and Kalavrizioti, Dimitra and Georgiou, Vasileios and Papathanasopoulos, Panagiotis and Mouzaki, Athanasia},
  title = {Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis},
  journal = {Multiple Sclerosis International},
  year = {2014},
  volume = {2014},
  pages = {1--8},
  doi = {10.1155/2014/436764}
}
Kostenlos starten →